BR9712138A - Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition. - Google Patents

Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition.

Info

Publication number
BR9712138A
BR9712138A BR9712138-0A BR9712138A BR9712138A BR 9712138 A BR9712138 A BR 9712138A BR 9712138 A BR9712138 A BR 9712138A BR 9712138 A BR9712138 A BR 9712138A
Authority
BR
Brazil
Prior art keywords
rna virus
isolated
segmented
negative
immunize
Prior art date
Application number
BR9712138-0A
Other languages
Portuguese (pt)
Inventor
Stephen A Udem
Mohinderjit S Sidhu
Joanne M Tatem
Brian R Murphy
Valerie B Randolph
Original Assignee
American Cyanamid Co
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co, Us Health filed Critical American Cyanamid Co
Publication of BR9712138A publication Critical patent/BR9712138A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"VìRUS DE RNA ISOLADO, VACINA, PROCESSO PARA IMUNIZAR UM INDIVìDUO PARA INDUZIR PROTEçãO CONTRA UM VìRUS DE RNA NãO SEGMENTADO, SENTIDO NEGATIVO, DE FILAMENTO úNICO, DA ORDEM MONONEGAVIRALES E PARA PRODUZIR VìRUS DE RNA, MOLéCULA DE áCIDO NUCLEICO ISOLADA E COMPOSIçãO". Vírus de RNA isolado, gerado de modo recombinante, atenuado, não segmentado, sentido negativo, de filamento único, da Ordem Mononegavirales, tendo pelo menos uma mutação atenuante na região de promotor genómico 3' e tendo pelo menos uma mutação atenuante no gene de polimerase de RNA são descritos. As vacinas são formuladas compreendendo estes vírus e um veículo fisiologicamente aceitável. As vacina são usadas para imunização de um indivíduo para induzir proteção contra um vírus de RNA não segmentado, sentido negativo, de filamento único, da Ordem Mononegavirales."ISOLATED RNA VIRUS, VACCINE, PROCESS TO IMMUNIZE AN INDIVIDUAL TO INDUCT PROTECTION AGAINST A NON-SEGMENTED, NEGATIVE, UNIQUE FILMARY, MONONEGAVIRAL ORDER, AND PRODUCTION OF NUCLEA, ROLE AND MOLE VIRUS ISOLATED. Isolated RNA virus, recombinantly generated, attenuated, non-segmented, negative, single-stranded, of the Order Mononegavirales, having at least one attenuating mutation in the 3 'genomic promoter region and having at least one attenuating mutation in the polymerase gene of RNA are described. Vaccines are formulated comprising these viruses and a physiologically acceptable carrier. Vaccines are used to immunize an individual to induce protection against a negative, single-stranded, non-segmented RNA virus of the Order Mononegavirales.

BR9712138-0A 1996-09-27 1997-09-19 Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition. BR9712138A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2682396P 1996-09-27 1996-09-27
PCT/US1997/016718 WO1998013501A2 (en) 1996-09-27 1997-09-19 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales

Publications (1)

Publication Number Publication Date
BR9712138A true BR9712138A (en) 2000-01-18

Family

ID=21833976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712138-0A BR9712138A (en) 1996-09-27 1997-09-19 Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition.

Country Status (8)

Country Link
EP (1) EP0932684A2 (en)
JP (1) JP2000517194A (en)
KR (1) KR20000048628A (en)
CN (1) CN1232504A (en)
AU (1) AU4427897A (en)
BR (1) BR9712138A (en)
CA (1) CA2265554A1 (en)
WO (1) WO1998013501A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
KR20010030630A (en) * 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 Attenuated respiratory syncytial viruses
EP1064358A2 (en) * 1998-03-26 2001-01-03 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
CA2333313C (en) * 1998-06-03 2011-11-08 American Cyanamid Company Novel methods for rescue of rna viruses
DK1098961T3 (en) 1998-06-12 2008-05-26 Andrej Y Dr Egorov Genesically attenuated viruses that induce interferon
EP2316924B1 (en) 1998-06-12 2017-10-11 Icahn School of Medicine at Mount Sinai Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
ATE343589T1 (en) * 2000-06-23 2006-11-15 Wyeth Corp MODOFIED MORBILLIVIRUS V PROTEINS
US7361496B1 (en) 2000-08-02 2008-04-22 Wyeth Rescue of mumps virus from cDNA
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
KR100964413B1 (en) 2001-01-19 2010-06-15 비로노바티브 비.브이. A virus causing respiratory tract illness in susceptible mammals
TWI359868B (en) 2002-02-21 2012-03-11 Medimmune Vaccines Inc Recombinant parainflulenza virus expression system
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CA2482946C (en) 2002-04-26 2013-09-17 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
EP1375670B1 (en) 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
ES2330309T3 (en) * 2002-06-20 2009-12-09 Institut Pasteur INFECTIOUS cDNA OF AN APPROVED VACCINE VIRUS strain of SARAMPION. USE FOR IMMUNOGENIC COMPOSITIONS.
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2004087062A2 (en) 2003-03-28 2004-10-14 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
EP2494987A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP4771959B2 (en) 2003-12-23 2011-09-14 メディミューン，エルエルシー Multiple plasmid systems for influenza virus production
CA2568015C (en) 2004-05-25 2013-08-27 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ES2552774T3 (en) 2004-06-01 2015-12-02 Icahn School Of Medicine At Mount Sinai Swine flu virus modified by genetic engineering and uses thereof
WO2006088481A2 (en) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
ES2527503T3 (en) 2005-03-08 2015-01-26 Medimmune, Llc Reordering influenza viruses
JP2008546408A (en) 2005-06-21 2008-12-25 メッドイミューン バクシーンズ，インコーポレイティド Methods and compositions for expressing heterologous proteases
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
HUE037464T2 (en) 2005-12-02 2018-08-28 Icahn School Med Mount Sinai Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
KR101436176B1 (en) 2006-04-19 2014-09-02 메디뮨 엘엘씨 Methods and compositions for expressing negative-sense viral rna in canine cells
WO2008133701A1 (en) 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
CA2659267C (en) 2006-08-09 2016-12-13 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US7758868B2 (en) 2006-12-22 2010-07-20 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof
ES2523587T3 (en) 2007-06-18 2014-11-27 Medimmune, Llc Influenza B viruses that have alterations in the hemagglutinin polypeptide
WO2010006144A2 (en) 2008-07-11 2010-01-14 Medlmmune, Llc. Influenza hemagglutinin and neuraminidase variants
AU2009313615B2 (en) 2008-11-05 2012-11-29 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
ES2550179T3 (en) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Chimeric Newcastle disease viruses and uses thereof
RU2535970C2 (en) 2009-02-12 2014-12-20 МЕДИММЬЮН, ЭлЭлСи Influenza haemagglutinin and neuraminidase variants
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
EP3900740A1 (en) 2010-03-30 2021-10-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
EP2420242A1 (en) 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
CN103906843B (en) * 2011-06-08 2016-12-07 维什瓦斯·乔希 Double-mass model mammalian expression systems
AU2012317159B2 (en) 2011-06-08 2016-10-06 Vishwas Joshi Two plasmid mammalian expression system
EA201490659A1 (en) 2011-09-20 2014-11-28 Маунт Синай Скул Оф Медсин VACCINES AGAINST FLU VIRUS AND THEIR USE
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
CN108641002A (en) 2012-12-18 2018-10-12 西奈山伊坎医学院 Influenza virus vaccine and application thereof
GEP20196976B (en) 2013-03-14 2019-06-10 Sloan Kettering Cancer Center Memorial Newcastle disease viruses and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
SG10201801562PA (en) 2014-02-27 2018-04-27 Viralytics Ltd Combination method for treatment of cancer
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR20170122786A (en) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2 Pig Influenza Virus Vaccine
KR20180057610A (en) 2015-08-03 2018-05-30 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Brassiary deletion mutants, non-yeast vectors encoding brassiary deletion mutants, and uses thereof
WO2017031401A2 (en) 2015-08-20 2017-02-23 University Of Rochester Ns1 truncated virus for the development of canine influenza vaccines
WO2017031408A1 (en) 2015-08-20 2017-02-23 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
EP3337504A1 (en) 2015-08-20 2018-06-27 University of Rochester Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
WO2017210528A1 (en) 2016-06-03 2017-12-07 University Of Rochester Equine influenza virus live-attenuated vaccines
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
BR112020017354A2 (en) 2018-02-27 2020-12-15 University Of Rochester MULTIVALENT IMMUNOLOGICAL COMPOSITION, AND, METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST A PLURALITY OF EQUINE INFLUENCE VIRUS.
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
AR118202A1 (en) 2019-02-27 2021-09-22 Univ Rochester MULTIVALENT VACCINE AGAINST LIVE ATTENUATED VIRUS INFLUENZA FOR THE PREVENTION AND CONTROL OF EQUINE INFLUENZA VIRUS (EIV) IN HORSES
US11103576B1 (en) 2020-06-15 2021-08-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Measles virus vaccine expressing SARS-COV-2 protein(s)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JP3045581B2 (en) * 1991-10-14 2000-05-29 社団法人北里研究所 Measles vaccine virus strain identification method
AU687738B2 (en) * 1992-04-14 1998-03-05 Mount Sinai School Of Medicine Of The City University Of New York, The Genetically engineered attenuated viruses
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Attenuated respiratory syncytial virus vaccine compositions
TW275632B (en) * 1992-04-21 1996-05-11 American Cyanamid Co
EP0702085B2 (en) * 1994-07-18 2010-01-13 Conzelmann, Karl-Klaus, Prof. Dr. Recombinant infectious non-segmented negative strand RNA virus

Also Published As

Publication number Publication date
JP2000517194A (en) 2000-12-26
KR20000048628A (en) 2000-07-25
EP0932684A2 (en) 1999-08-04
CN1232504A (en) 1999-10-20
WO1998013501A2 (en) 1998-04-02
WO1998013501A3 (en) 1998-08-13
AU4427897A (en) 1998-04-17
CA2265554A1 (en) 1998-04-02

Similar Documents

Publication Publication Date Title
BR9712138A (en) Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition.
BR9812232A (en) Human respiratory syncytial virus (rsv) human subgroup b, isolated, recombinantly generated, attenuated, vaccine, process to immunize an individual to induce protection against rsv subgroup b, composition, process to produce attenuated infectious rsv subgroup b, and isolated acid molecule nucleic
ATE138384T1 (en) OLIONUCLEOTIDE ALKYLPHOSPHONATE AND PHOSPHONOTHIOATE
BR0111827A (en) Isolated, recombinantly generated, non-segmented, negative-sense, single-stranded rna virus, genus morbillivirus, immunogenic composition, method for immunizing an individual to induce protection against said virus, method for reducing repression caused by a genus v protein morbillivìrus, isolated nucleotide sequence, composition, and method for producing an infectious morbillivìrus
DE69536039D1 (en) A host cell containing a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
BR9201848A (en) PROCESS FOR THE PREPARATION OF VIRUS PARTICUALS FOR VACCINES, VACCINE, AND, PROCESS FOR THE TREATMENT OR PROPHYLAXIS OF A VIRAL INFECTION IN A MAMMALIAN WITH THE SAME NEED
ES2087055T3 (en) PLANT PROTECTION AGAINST VIRAL INFECTION.
ATE257175T1 (en) RECOMBINANT INFECTIOUS NON-SEGMENTED, NEGATIVE STRAND RNA VIRUS
BR9712592A (en) Process to generate an infectious clone, recombinant nucleic acid, its molecule, modified RNA virus, cell infected with it, vaccine, protein and / or antigen, and diagnostic test
GR3035458T3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
PT100472A (en) GENETIC SEQUENCES OF HEPATITIS C VIRUSES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM FOR DIAGNOSIS AND THERAPEUTIC HEPATITIS C
KR900700603A (en) Ribozyme
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
ATE73348T1 (en) THYMIDINE KINASE DELETION MUTANTS OF BOVINE HERPESVIRUS-1, VACCINES AGAINST BOVINE RHINOTRACHEITIS CONTAINING THEM, AND METHODS FOR THEIR MANUFACTURE AND USE.
BR0012938A (en) Method for producing a recombinant mumps virus, recombinant mumps virus, composition, method for immunizing an individual, nucleic acid molecule, plasmid, host cell, pharmaceutical composition, and nucleotide sequence
BR9815285A (en) Alphaviruses for paramyxoviruses vaccine
ES8608581A1 (en) Synthetic genes for bovine parainfluenza virus
BR9707400A (en) Vaccines against gene 63 product of varicella zoster virus.
Kaper et al. Cucumber mosaic virus-associated RNA 5 V. Extensive nucleotide sequence homology among CARNA 5 preparations of different CMV strains
BR9610932A (en) Process for storing microorganisms, microorganism composition and use
CA2258675A1 (en) 2-cyclopenten-1-one as an inducer of hsp70
HUP0102517A2 (en) Genomic sequences upstream of the coding region of the ifn-alpha2 gene for protein production and delivery
PT1254663E (en) ANTIVIRAL AGENT
FI893346A (en) ICKE-REVERTERANDE RNA VIRUS.
BR9708720A (en) Pharmaceutical composition and process for the treatment of HIV dementia.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO, DE ACORDO COM ARTIGO 8O DA LPI